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This manuscript reports the synthesis of a series of N-substituted derivatives of 2-phenitidine. First, 
the reaction of 2-phenitidine (1) with benzene sulfonyl chloride (2) yielded N-(2-ethoxyphenyl) 
benzenesulfonamide (3), which further on treatment with sodium hydride and alkyl halides (4a-g) 
furnished into new sulfonamides (5a-g). Second, the phenitidine reacted with benzoyl chloride (6) 
and acetyl chloride (8) to yield the reported N-benzoyl phenitidine (7) and N-acetyl phenitidine (9), 
respectively. These derivatives were characterized by infrared spectroscopy, 1H-NMR, and EI-MS, and 
then screened against acetylcholinesterase, butylcholinesterase, and lipoxygenase enzyme, and were 
found to be potent inhibitors of butyrylcholinesterase alone.
Uniterms: 2-Phenitidine/inhibitor activity. Sulfonamides. Acetamide. Benzamide. Butyrylcholinesterase.
Este trabalho apresenta a síntese de uma série de derivados da 2-fenetidina N-substituídos. Primeiro, 
a reação da 2-fenetidina (1) com cloreto de benzenossulfonila (2) conduziu à N-(2-etoxifenil)
benzenossulfonamida (3) que, após tratamento com hidreto de sódio e haletos de alquila (4a-g), originou 
novas sulfonamidas (5a-g). Em segundo lugar, a reação da fenetidina com cloreto de benzoíla (6) e 
cloreto de acetila (8) conduziu, respectivamente, à N-benzoilfenetidina (7) e N-acetilfenetidina (9). A 
caracterização destes derivados fez-se por IV, 1H-RMN e EM-IE. Procedeu-se à avaliação da atividade 
inibidora destes compostos em relação às enzimas acetilcolinesterase, butirilcolinesterase e lipoxigenase. 
No entanto, apenas revelaram atividade inibidora da butirilcolinesterase.
Unitermos: 2-Fenetidina/atividade inibidora. Sulfonamidas. Acetamida. Benzamida. Butirilcolinesterase. 
INTRODUCTION
Compounds bearing the -SO2-NH- group (the 
sulfonamide group) have long been known to be potent 
inhibitors of carbonic anhydrase (CA) (Remko et al., 2010; 
Supuran et al., 2003), and are widely used as antibacterial 
agents. Synthesis of sulfonamides involves the nucleo-
philic attack of ammonia or amine on a sulfonyl halide 
(Chan et al., 2002; Shaabani et al., 2007). On the other 
hand, arylsulfonyl azides can be reduced to convert into 
arylsulfonamides (Boruah et al., 1997). It is also known 
that aryl sulfonamides act as antitumor agents through 
the perturbation of the cell cycle in the G1 phase, during 
angiogenesis inhibition or distribution of the microtubule 
assembly (Saczewski et al., 2008; Garaj et al., 2005; 
Saczewski et al., 2006; Supuran et al., 2003). Various 
sulfonamides have also been reported to act as antitumor 
agents through carbonic anhydrase (CA) inhibition (Su-
puran et al., 2003; Supuran et al., 2004; Kivela et al., 2005; 
Supuran et al., 2007).
Acetylcholinesterase (AChE, EC 3.1.1.7) and butyr-
ylcholinesterase (BChE, EC 3.1.1.8) consist of a family of 
enzymes, which include serine hydrolases. The different 
specificities for the substrates and the inhibitors for these 
enzymes are due to the differences in the amino acid resi-
dues of the active sites of AChE and BChE. The enzyme 
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system is responsible for the termination of acetylcholine 
at the cholinergic synapses. These are key components of 
cholinergic brain synapses and neuromuscular junctions. 
The major functions of AChE and BChE are to catalyze 
the hydrolysis of the neurotransmitter acetylcholine, and 
to terminate the nerve impulse at the cholinergic synapses 
(Cygler et al., 1993; Tougu et al., 2001). It has been found 
that BChE (E.C 3.1.1.8) inhibition is an effective tool for 
the treatment of Alzheimer’s disease and related demen-
tias. BChE is found in significantly higher quantities in 
Alzheimer’s plaques than in plaques found among normal 
age-related brains without dementia. BChE is produced 
in the liver and enriches blood circulation. In addition, 
it is also present in adipose tissue, and can also be found 
in the intestine, smooth muscle cells, white matter of the 
brain, and in many other tissues (Gauthier et al., 2001). 
Therefore, the search for new cholinesterase inhibitors 
is considered an important and ongoing strategy in the 
introduction of new drug candidates for the treatment of 
Alzheimer’s disease and other related diseases (Bertaccini 
et al., 1982).
In this work, we report on the various N-substituted 
derivatives of 2-phenitidine. First, a new parent sulfon-
amide [N-(2-ethoxyphenyl)benzenesulfonamide] was 
prepared by reacting benzenesulfonyl chloride with 
2-phenitidine at room temperature in excellent yield. 
Simple stirring in basic media gave the desired compound 
that was further processed to obtain different new N-alkyl 
substituted sulfonamides, and then 2-phenitidine was also 
acylated with benzoyl chloride and acetyl chloride, which 
have already been reported (Downer, Jackson, 2007; Smith 
et al., 2003).
A survey of the literature revealed that slight modi-
fications in the structure can result in qualitative as well 
as quantitative changes in activity, which prompted us to 
undertake the synthesis of various 2-phenitidine deriva-
tives and to study their structure-activity relationship by 
screening them against DPPH, AChE, BChE, and lipoxy-
genase (LOX), and these were found to be active against 
BChE, and were also possible entrants for the treatment 
of Alzheimer’s disease.
MATERIALS AND METHODS
General
Thin-layer chromatography (TLC) was performed 
on pre-coated silica gel G-25-UV254 plates. Detection was 
carried out at 254 nm with a ceric sulphate reagent. Purity 
was checked on TLC with different solvent systems using 
ethyl acetate and n-hexane, giving a single spot. The infra-
red (IR) spectra were recorded in KBr on a Jasco-320-A 
spectrophotometer (wave number in cm-1). 1H-NMR 
spectra were recorded in CDCl3 on a Bruker spectrometer 
operating at 400 MHz. Chemical shifts are given in ppm. 
Mass spectra (EI-MS) were recorded on a JMS-HX-110 
spectrometer with a data system. The melting points were 
recorded on a Griffin and George melting point apparatus 
by open capillary tube, and these were uncorrected.
Procedure for the synthesis of sulfonamide in 
aqueous media
The nucleophilic substitution reaction of amine 
with benzene sulfonyl chloride was carried out as fol-
lows: a mixture of benzenesulfonyl chloride (10.0 mmol; 
1.27 mL) and 2-phenitidine (10.0 mmol; 1.43 mL) was 
suspended in 25 mL of water. The pH of the suspension 
was adjusted and was maintained at 9.0 by adding a basic 
aqueous solution at room temperature. The reaction solu-
tion was stirred and monitored with TLC, and it took 2 
hours for the completion of the reaction. Then, concen-
trated HCl was gradually added to adjust the pH to 2.0. 
The precipitates were collected by filtration, washed with 
distilled water, and dried to afford the title compound 3. 
The product was dissolved in methanol and recrystallized 
by slow evaporation of the solvent in order to generate col-
orless, bead-like crystals of N-(2-ethoxyphenyl) benzene-
sulfonamide (yield 89%; m.p. 88 oC).
General procedure for the synthesis of N-alkyl 
substituted sulfonamides in DMF
The calculated amount of 3 (0.1 mmol) was taken in 
a round-bottomed flask (50 mL), and dimethyl formamide 
(DMF; 10 mL) was added to dissolve it; sodium hydride 
(0.1 mmol) was then added to the mixture. The mixture 
was stirred for 30 minutes at room temperature, then the 
alkyl halide was slowly added to the mixture, and the 
solution was stirred for a further 3 hours. The progress 
of the reaction was monitored via TLC till single spot. 
The product was precipitated by adding water. It was fil-
tered, washed with water, and crystallized from aqueous 
methanol.
General procedure for the synthesis of N-acylated 
derivatives
The calculated amount of 1 was taken in the round-
bottomed flask (50 mL), then a small amount of sodium 
carbonate (Na2CO3) was added to make the medium basic. 
Acyl chloride (8 and 10 separately) was then added, and 
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the solution was shaken vigorously. The evolved CO2 was 
liberated at intervals. The reaction progress was monitored 
with TLC till single spot. After completion of the reaction, 
water was added, and the precipitates that were formed 
were filtered and dried.
Acetylcholinesterase assay
AChE inhibition activity was performed according 
to the method of Ellman et al. (1961) with slight modi-
fications. The total volume of the reaction mixture was 
100 µL. It contained 60 µL of Na2HPO4 buffer with a 
concentration of 50 mM and a pH of 7.7. Following this, 
10 µL of the test compound (0.5 mM well-1) was added, 
followed by the addition of 10 µL (0.005 unit well-1) of 
enzyme. The contents were mixed and preread at 405 nm, 
then contents were preincubated for 10 minutes at 37 ºC. 
The reaction was initiated by the addition of 10 µL of 
0.5 mM well-1 substrate (acetylthiocholine iodide), fol-
lowed by the addition of 10 µL of DTNB (0.5 mM well-1). 
After 15 minutes of incubation at 37ºC, absorbance was 
measured at 405 nm. A Synergy HT (BioTek, USA) 96-
well plate reader was used in all experiments. All experi-
ments were carried out with their respective controls in 
triplicate. Eserine (0.5 mM well-1) was used as a positive 
control. The percent of inhibition was calculated using 
the following equation:
Butyrylcholinesterase assay
BChE inhibition activity was performed according 
to the method of Ellman et al. (1961) with slight modi-
fications. The total volume of the reaction mixture was 
100 µL containing 60 µL of the Na2HPO4 buffer (50 mM 
and a pH of 7.7). A total of 10 µL of the test compounds 
of 0.5 mM well-1 were added, followed by the addition 
of 10 µL (0.5 unit well-1) of BChE. The contents were 
mixed and preread at 405 nm and then preincubated for 
10 minutes at 37 ºC. The reaction was initiated by the 
addition of 10 µL of the 0.5 mM well-1 substrate (butyryl-
thiocholine bromide) followed by the addition of 10 µL 
of DTNB, 0.5 mM well-1. After 15 minutes of incubation 
at 37 ºC, absorbance was measured at 405 nm. A Synergy 
HT (BioTek, USA) 96-well plate reader was used in all 
experiments. All experiments were carried out with their 
respective controls in triplicate. Eserine (0.5 mM well-1) 
was used as a positive control. The percent of inhibition 
was calculated by the help of following equation:
IC50 values (the concentration at which there is 50% 
enzyme inhibition) of the compounds were calculated us-
ing the EZ-Fit Enzyme kinetics software (Perella Scientific 
Inc., Amherst, USA).
Lipoxygenase assay
LOX activity was assayed according to the reported 
method (Clapp et al., 1985; Kemal et al., 1987), but with 
slight modifications. A total volume of 200 µL of the as-
say mixture contained 150 µL sodium phosphate buffer 
(100 mM, pH 8.0), 10 µL of the test compound, and 15 µL 
of the purified LOX enzyme (Sigma, USA). The contents 
were mixed and preread at 234 nm, and then preincubated 
for 10 minutes at 25 °C. The reaction was initiated by the 
addition of 25 µL of substrate solution. The change in 
absorbance was observed after 6 minutes at 234 nm. A 
Synergy HT (BioTek, USA) 96-well plate reader was used 
in all experiments. All reactions were performed in tripli-
cate. The positive and negative controls were included in 
the assay. Quercetin (0.5 mM well-1) was used as a positive 
control. The percentage of inhibition was calculated by the 
formula given below:
where Control = Total enzyme activity without inhibitor; 
Test = Activity in the presence of the test compound.
DPPH assay
The stable 1,1-diphenyl-2-picrylhydrazyl radical 
(DPPH) was used for the determination of antioxidant 
activity. Different concentrations of the compounds in 
their respective solvents were added at an equal volume 
(10 µL) to 90 µL of 100 µM of methanolic DPPH in a 
total volume of 100 µL in 96-well plates. The contents 
were mixed and incubated at 37 oC for 30 minutes. The 
absorbance was measured at 517 nm using a Synergy 
HT BioTek® USA microplate reader. Quercetin and 
L -ascorbic acid were used as standard antioxidants. The 
experiments were carried out in triplicate. IC50 values 
were calculated using the EZ-Fit5 (Perrella Scientific 
Inc., Amherst, USA) software. The decrease in absor-
bance indicates increased radical scavenging activity, 
which was determined by the following formula (Huang 
et al., 2005):
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Structural characterization
N-(2-Ethoxyphenyl)benzenesulfonamide (3)
Dark brown beads, yield 89%, m.p. 88 oC; IR (KBr): 
nmax: 3430 (N-H), 3056 (Ar-H), 1341 (-SO2-NH-), 1258 
(Ar-O-R); EIMS: m/z 277 [M]+, 232 [M-OC2H5]+, 213 
[M-SO2]+, 141[C6H5SO2]+.
N-Methyl-N-(2-ethoxyphenyl)benzenesulfonamide (5a)
Dark brown powder, yield 83%, m.p. 70 oC; IR 
(KBr): nmax: 3466 (N-R), 3040 (Ar-H), 1344 (-SO2-NR-), 
1279 (Ar-O-R); EIMS: m/z 291 [M]+, 246 [M-OC2H5]+, 
227 [M-SO2]+, 141 [C6H5SO2]+.
N-Ethyl-N-(2-ethoxyphenyl)benzenesulfonamide (5b)
Dark brown powder, yield 86%, m.p. 54 oC IR 
(KBr): nmax: 3401 (N-R), 3031 (Ar-H), 1343 (-SO2-NR-), 
1260 (Ar-O-R); EIMS: m/z 305 [M]+, 260 [M-OC2H5]+, 
241 [M-SO2]+, 141 [C6H5SO2]+.
N-Isopropyl-N-(2-ethoxyphenyl)benzenesulfonamide 
(5c)
Dark brown powder, yield 81%, m.p. 60 oC. IR 
(KBr): nmax: 3432 (N-R), 3075 (Ar-H), 1323 (-SO2-NR-), 
1268 (Ar-O-R); EIMS: m/z 319 [M]+, 274 [M-OC2H5]+, 
255 [M-SO2]+, 141 [C6H5SO2]+.
N-Propyl-N-(2-ethoxyphenyl)benzenesulfonamide (5d)
Dark brown powder, yield 89%, m.p. 56 oC IR 
(KBr): nmax: 3467 (N-R), 3065 (Ar-H), 1343 (-SO2-NR-) 
1255 (Ar-O-R); EIMS: m/z 319 [M]+, 264 [M-OC2H5]+, 
255 [M-SO2]+, 141 [C6H5SO2]+.
N-Butyl-N-(2-ethoxyphenyl) benzenesulfonamide (5e)
Dark brown powder, yield 82%, m.p. 59 oC. IR 
(KBr): nmax: 3484 (N-R), 3049 (Ar-H), 1315 (-SO2-NR-), 
1286 (Ar-O-R); EIMS: m/z 333 [M]+, 288 [M-OC2H5]+, 
269 [M-SO2]+, 141 [C6H5SO2]+.
N-Pentyl-N-(2-ethoxyphenyl)benzenesulfonamide (5f)
Dark brown powder, yield 84%, m.p. 58 oC. IR 
(KBr): nmax: 3452 (N-R), 3063 (Ar-H), 1311 (-SO2-NR-), 
1263 (Ar-O-R); EIMS: m/z 347 [M]+, 302 [M-OC2H5]+, 
283 [M-SO2]+, 141 [C6H5SO2]+.
N-Allyl-N-(2-ethoxyphenyl)benzenesulfonamide (5g)
Gummy solid, yield 80%. IR (KBr): nmax: 3488 
(N-R), 3286 (Ar-H), 1313 (-SO2-NR-), 1255 (Ar-O-R); 
EIMS: m/z 317 [M]+, 272 [M-OC2H5]+, 253 [M-SO2]+, 
141 [C6H5SO2]+.
N-Benzoyl-2-ethoxyaniline (7)
Gummy solid, yield 83%. IR (KBr): nmax: 3429 (N-
H), 3067 (Ar-H), 1253 (Ar-O-R); EIMS: m/z 241 [M]+, 
196 [M-OC2H5]+, 213 [M-CO]+, 105 [C6H5CO]+.
N-Acetyl-2-ethoxyaniline (9)
Gummy solid, yield 87%. IR (KBr): nmax: 3424 (N-
H), 3034 (Ar-H), 1244 (Ar-O-R); EIMS: m/z 179 [M]+, 
134 [M-OC2H5]+, 151 [M-CO]+, 43 [CH3CO]+.
RESULTS AND DISCUSSION
The designed N-substituted new derivatives of 
2-phenitidine were synthesized according to Figure 1. The 
parent compound 3 was synthesized as dark brown beads. 
The molecular formula, C14H15NO3S, was established 
with the help of EI-MS showing a molecular ion peak at 
m/z 277, and by counting the number of protons in the 
1H-NMR spectrum (Table-I). Its IR spectrum revealed the 
presence of an ethoxy group (1258 cm-1), a sulfonyl group 
FIGURE 1 - Synthesis of 2-phenitidine derivatives 5a-g, 7, and 9.
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TABLE I - 1H-NMRa data (CDCl3) of compounds 3, 5a-g , 7 , 9. d in ppm, J in Hz
C.No. 3 5a 5b 5c 5d 5e 5f 5g 7 9
d (H) d (H) d (H) d (H) d (H) d (H) d (H) d (H) d (H) d (H)
1 - - - - - - - - - -
2 - - - - - - - - - -
3 6.67 (dd, 
J = 1.0, 7.6 )
6.74 (dd, 
J = 1.0, 8.0)
6.74 (dd, 
J = 1.2, 8.4)
6.68 (dd, 
J = 1.0, 8.0)
6.73 (dd, 
J = 1.0, 8.4)
6.72 (dd, 
J = 1.0, 8.4)
6.74 (dd, 
J = 1.0, 8.4)
6.8 (dd, 
J = 1.0, 8.0)
6.88 (dd, 
J = 1.2, 7.6)
6.84 (dd, 
J = 1.0, 7.6)
4 7.00 (ddd, 
J = 1.2, 7.6, 
8.0 )
7.24 (ddd, 
J = 1.6, 7.6, 
8.0)
7.24 (ddd, J = 
1.6, 7.6, 8.0)
7.28 (ddd, J = 
1.6, 8.4, 8.0)
7.24 (ddd, J = 
1.6, 7.6, 8.0)
7.20 (ddd, J = 
1.6, 8.0, 8.0)
7.24 (ddd, J = 
1.6, 8.0, 8.4)
7.21 (ddd, 
J = 1.6, 8.4, 8.4)
7.04 (ddd, 
J = 2.0, 7.6, 
8.0)
6.98 (ddd, 
J = 1.2, 7.6, 
8.0)
5 6.87 (ddd, 
J = 1.2, 7.6, 
8.0)
6.91 (ddd, 
J = 1.6, 8.0, 
8.0)
6.91 (ddd, 
J = 1.2, 7.6, 7.6)
6.89 (ddd, 
J = 1.2, 7.6, 7.6)
6.91 (ddd, 
J = 1.2, 7.6, 7.6)
6.91 (ddd, 
J = 1.0 7.2, 
7.6)
6.91 (ddd, 
J = 1.2, 7.6, 
7.6)
6.87 (ddd, 
J = 1.2 ,7.6, 8.4)
6.99 (ddd, 
J = 1.6, 7.6, 
7.6)
6.91 (ddd, 
J = 1.2, 7.6, 
8.0)
6 7.52 (dd, 
J = 1.2, 7.6 )
7.36 (dd, J = 
2.0, 8.0)
7.31 (dd, 
J = 1.6, 7.6)
7.13 (dd, 
J = 1.6, 7.6)
7.30 (dd, 
J = 2.0, 8.0)
7.31 (dd, 
J = 2, 8.0)
7.32 (dd, 
J = 1.6, 7.6)
7.27 (dd, 
J = 1.6, 7.6)
8.52 (dd, 
J = 1.6, 7.6)
8.33 (br d, 
J = 7.6)
1' - - - - - - - - - 2.18 (s)
2' 7.71 (dd, 
J = 1.6, 8.8)
7.66 (dd, 
J = 1.6, 8.8)
7.66 (dd, 
J = 1.2, 8.4)
7.82 (dd, 
J = 1.2, 8.4)
7.63 (dd, 
J = 1.2, 7.2)
7.63 (dd, 
J = 1.2, 7.2)
7.63 (dd, 
J = 1.2, 8.8)
7.63 (dd, 
J = 1.2, 8.4)
7.88 (dd, 
J = 1.6, 8.4)
-
3' 7.36 (br t, 
J = 7.6)
7.41 (br t, 
J = 7.6)
7.38 (br t, 
J = 7.2)
7.41 (br t, 
J = 7.2)
7.38 (br t, 
J = 8.0)
7.39 (br t, 
J = 7.6)
7.38 (br.t, 
J = 7.6)
7.38 (br t, 
J = 7.2)
7.45 (br t, 
J = 8.6)
-
4' 7.47 (br t, 
J = 7.6 )
7.51 (br t, 
J = 7.6)
7.48 (br t, 
J = 7.6)
7.49 (br t, 
J = 7.6)
7.48 (br t, 
J = 7.6)
7.49 (br t, 
J = 7.6)
7.49 (br.t, 
J = 7.6)
7.48 (br t, 
J = 7.6)
7.54 (br t, 
J = 8.2)
-
5' 7.36 (br t, 
J = 7.6)
7.41 (br t, 
J = 7.6)
7.38 (br t, 
J = 7.2)
7.41 (br t, 
J = 7.2)
7.38 (br t, 
J = 8.0)
7.39 (br t, 
J = 7.6)
7.38 (br.t, 
J = 7.6)
7.38 (br t, 
J = 7.2)
7.45 (br t, 
J = 8.6)
-
6' 7.71 (dd, 
J = 1.6, 8.8)
7.66 (dd,
J = 1.6, 8.8)
7.66 (dd, 
J = 1.2, 8.4)
7.82 (dd, 
J = 1.2, 8.4)
7.63 (dd, 
J = 1.2, 7.2)
7.63 (dd, 
J = 1.2, 7.2)
7.63 (dd, 
J = 1.2, 8.8)
7.63 (dd, 
J = 1.2, 8.4)
7.88 (dd, 
J = 1.6, 8.4)
-
1" 3.78 (q, 
J = 7.2)
3.64 (q, 
J = 6.8)
3.64 (m, 2H) 3.83 (q, 
J = 6.8)
3.59 (m, 4H) 3.59 (m, 2H, 
CH2-1′′),
3.59 (m) 4.20 (m) 4.14 (q, 
J = 6.8)
-
2" 1.22 (t, 
J = 7.2)
0.93 (t, 
J = 6.8)
0.94 (t, J = 7.2) 1.20 (t, 
J = 6.8)
0.93 (t, 
J = 6.8)
0.93 (t, 
J = 6.8)
0.93 (t, 
J = 6.8)
0.92 (t, 
J = 6.8)
1.47 (t, 
J = 6.8)
-
1'" - 3.21( s) 3.64 (m, 
CH2-1′′)
4.35 (septet, 
J = 6.4)
3.59 (m, 4H) 3.59 (m) 3.59 (m) 4.20 (m) 4.09 (q,
J = 6.8)
2'" - - 1.05 ( t, J = 7.2) 1.08 (d, 
J = 6.4)
1.30 (m) 1.38 (m) 1.40 (m) 5.76 (m) 1.43 (t, 
J = 6.8)
3'" - - - 1.08 (d, 
J = 6.4)
0.83 (t, 
J = 7.2)
1.32 (m) 1.26 ( m) 5.03 (dd, J =1.6, 
17.3 Hb) & , 4.96 
(dd , J =1.2, 10 
Hz, Ha)
- -
4'" - - - - - 0.83 (t, 
J =7.2)
1.24 (m) - - -
5'" - - - - - 0.82 (t, 
J = 7.2)
- - -
a All spectra were recorded at 400 MHz.
(1341 cm-1), and a –NH group (3430 cm-1) in the molecule. 
The EI-MS also gave a distinct peak at m/z 213 after the 
removal of the –SO2 group, and a further two fragments of 
ion peaks were observed at m/z 232 [M-OC2H5]+ and 141 
[C6H5SO2]+, which showed the presence of ethoxy and 
benzene sulfonyl groups, respectively, in the molecule. In 
its 1H-NMR spectrum, the signals in the aromatic region 
appeared at δ 7.52 (dd, J = 1.2,7.6 Hz, H-6), 7.00 (ddd, J 
= 1.2,7.6,8.0 Hz, H-4), 6.87 (ddd, J = 1.2,7.6,8.0 Hz, H-5), 
and 6.67 (dd, J = 1.0,7.6 Hz, H-3), which were assigned to 
the protons of the disubstituted ring of phenitidine, and the 
signals appearing at δ 7.71 (dd, J = 1.6,8.8 Hz, 2H, H-2' 
& H-6'), 7.47 (brt, J = 7.6 Hz, H-4'), and 7.36 (br t, J = 7.6 
Hz, H-3' & H-5') were typical for the protons of the mono-
substituted ring derived from benzenesulphonyl chloride. 
Moreover, a characteristics quartet at δ 3.78 (q, J = 7.2 Hz, 
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2H, H2-1’’) and a triplet at δ 1.22 (t, J = 7.2 Hz, 3H, H3-2’’) 
revealed the presence of an ethoxy group in the molecule. 
On the basis of the cumulative evidence reported above, 
the structure of 3 was assigned as N-(2-ethoxyphenyl) 
benzenesulfonamide, which is a new sulfonamide. Simi-
larly, on the basis of spectral evidences from IR, EI-MS 
(experimental section) and, 1H-NMR (Table I), the struc-
tures of other derivatives of 2-phenitidine were elucidated 
as described in Figure 1.
The screening of these derivatives showed that 
these were inactive against LOX and AChE, but they 
exhibited moderate inhibitory potential against BChE, as 
evident from their IC50 values (Table II). Among these, N-
isopropyl-N-(2-ethoxyphenyl) benzenesulfonamide (5c) 
was found to be the most suitable inhibitor, having an IC50 
value of 07 ± 0.81 µmoles/L relative to eserine, a reference 
standard, with an IC50 value of 0.85 ± 0.001 µmoles/L, 
probably due to the substitution of the isopropyl group 
(a branched chain) in this molecule. Antioxidant activity 
using the DPPH method showed little antioxidant activity 
of these compounds; the highest activity was shown by 5f 
(46.56% ± 1.02% at 0.5 mM) and the lowest activity by 
parent compound 3 (9.10% ± 0.59% at 0.5 mM). All other 
compounds showed antioxidant activity between these two 
extremes. The present investigation generally concluded 
that the synthesized 2-phenitidine derivatives, 5a-5g, 7, 
and 9 – due to their suitable structural features – could be 
used as valuable inhibitors of BChEs, and that these are 
also ideally suited for further structural modification to 
obtain more potent and less cytotoxic therapeutic agents 
for the treatment of Alzheimer’s disease.
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